Skip to content

Study · Animal study (in vivo) · rat · 2015

4 results

Pentadecapeptide BPC 157 Reduces Bleeding and Thrombocytopenia after Amputation in Rats Treated with Heparin, Warfarin, L-NAME and L-Arginine.

Stupnisek M, Kokot A, Drmic D, Hrelec Patrlj M, Zenko Sever A, Kolenc D, Radic B, Suran J, Bojic D, Vcev A, Seiwerth S, Sikiric P

PloS one21 Apr 2015Cited by 59 (Europe PMC)

PMID25897838 (opens in a new tab)PMCIDPMC4405609 (opens in a new tab)DOI10.1371/journal.pone.0123454 (opens in a new tab)PepBankPUB-25897838
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

BackgroundBPC 157 is a stable gastric pentadecapeptide recently implicated with a role in hemostasis. While NO is largely implicated in hemostatic mechanisms, in tail-amputation-models under heparin- and warfarin-administration, both the NO-synthase (NOS)-blocker, L-NAME (prothrombotic) and the NOS-substrate L-arginine (antithrombotic), were little investigated. Objective. To investigate the effect of L-NAME and L-arginine on hemostatic parameters, and to reveal the effects of BPC 157 on the L-NAME- and L-arginine-induced hemostatic actions under different pathological condition: tail amputation without or with anticoagulants, heparin or warfarin.MethodsTail amputation, and/or i.v.-heparin (10 mg/kg), i.g.-warfarin (1.5 mg/kg/day for 3 days) were used in rats. Treatment includes BPC 157, L-NAME, L-arginine, per se and their combination.ResultsAfter (tail) amputation, with or without i.v.-heparin or i.g.-warfarin, BPC 157 (10 μg/kg, 10 ng/kg, i.p., i.v. (heparin), 10 μg/kg i.g. (warfarin)) always reduced bleeding time and/or haemorrhage and counteracted thrombocytopenia. As for L-NAME and/or L-arginine, we noted: L-arginine (100 mg/kg i.p.)-rats: more bleeding, less/no thrombocytopenia; L-NAME (5 mg/kg i.p.)-rats: less bleeding (amputation only), but present thrombocytopenia; L-NAME+L-arginine-rats also exhibited thrombocytopenia: L-NAME counteracted L-arginine-increased bleeding, L-arginine did not counteract L-NAME-thrombocytopenia. All animals receiving BPC 157 in addition (BPC 157 μg+L-NAME; BPC 157 μg+L-arginine, BPC 157 μg+L-NAME+L-arginine), exhibited decreased haemorrhage and markedly counteracted thrombocytopenia.ConclusionsL-NAME (thrombocytopenia), L-arginine (increased haemorrhage) counteraction and BPC 157 (decreased haemorrhage, counteracted thrombocytopenia) with rescue against two different anticoagulants, implicate a BPC 157 modulatory and balancing role with rescued NO-hemostatic mechanisms.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats after tail amputation, with or without heparin or warfarin, BPC‑157 reduced bleeding time and/or haemorrhage.

    In plain wordsIn rats after tail amputation, with or without blood thinners, BPC‑157 reduced bleeding time and/or bleeding.

    Peptide
    BPC-157
    Outcome
    DecreaseBleeding time and/or haemorrhage after tail amputation, with or without heparin or warfarin
    Study

    ratn: not reported in source

    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg (10 µg/kg for warfarin) · intraperitoneal, intravenous (heparin) or intragastric (warfarin)As given in this study (rat).

    Source sentences

    Summary
    After (tail) amputation, with or without i.v.-heparin or i.g.-warfarin, BPC 157 (10 μg/kg, 10 ng/kg, i.p., i.v. (heparin), 10 μg/kg i.g. (warfarin)) always reduced bleeding time and/or haemorrhage and counteracted thrombocytopenia.
    2 context sentences
    Summary · context
    Tail amputation, and/or i.v.-heparin (10 mg/kg), i.g.-warfarin (1.5 mg/kg/day for 3 days) were used in rats.
    Summary · context
    Treatment includes BPC 157, L-NAME, L-arginine, per se and their combination.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats after tail amputation, with or without heparin or warfarin, BPC‑157 counteracted thrombocytopenia.

    In plain wordsIn rats after tail amputation, with or without blood thinners, BPC‑157 counteracted the drop in platelet count.

    Peptide
    BPC-157
    Outcome
    DecreaseThrombocytopenia after tail amputation, with or without heparin or warfarin
    Study

    ratn: not reported in source

    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg (10 µg/kg for warfarin) · intraperitoneal, intravenous (heparin) or intragastric (warfarin)As given in this study (rat).

    Source sentences

    Summary
    After (tail) amputation, with or without i.v.-heparin or i.g.-warfarin, BPC 157 (10 μg/kg, 10 ng/kg, i.p., i.v. (heparin), 10 μg/kg i.g. (warfarin)) always reduced bleeding time and/or haemorrhage and counteracted thrombocytopenia.
    2 context sentences
    Summary · context
    Tail amputation, and/or i.v.-heparin (10 mg/kg), i.g.-warfarin (1.5 mg/kg/day for 3 days) were used in rats.
    Summary · context
    Treatment includes BPC 157, L-NAME, L-arginine, per se and their combination.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats given L-NAME, L-arginine or both, adding BPC‑157 decreased haemorrhage.

    In plain wordsIn rats given L-NAME, L-arginine or both, adding BPC‑157 reduced bleeding.

    Peptide
    BPC-157
    Outcome
    DecreaseHaemorrhage when BPC 157 was added to L-NAME and L-arginine
    Study

    ratn: not reported in source

    Comparator
    L-NAME and L-arginine without BPC 157
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg (10 µg/kg for warfarin) · intraperitoneal, intravenous (heparin) or intragastric (warfarin)As given in this study (rat).

    Source sentences

    Summary
    All animals receiving BPC 157 in addition (BPC 157 μg+L-NAME; BPC 157 μg+L-arginine, BPC 157 μg+L-NAME+L-arginine), exhibited decreased haemorrhage and markedly counteracted thrombocytopenia.
    2 context sentences
    Summary · context
    Tail amputation, and/or i.v.-heparin (10 mg/kg), i.g.-warfarin (1.5 mg/kg/day for 3 days) were used in rats.
    Summary · context
    Treatment includes BPC 157, L-NAME, L-arginine, per se and their combination.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats given L-NAME, L-arginine or both, adding BPC‑157 markedly counteracted thrombocytopenia.

    In plain wordsIn rats given L-NAME, L-arginine or both, adding BPC‑157 markedly counteracted the drop in platelet count.

    Peptide
    BPC-157
    Outcome
    DecreaseThrombocytopenia when BPC 157 was added to L-NAME and L-arginine
    Study

    ratn: not reported in source

    Comparator
    L-NAME and L-arginine without BPC 157
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg (10 µg/kg for warfarin) · intraperitoneal, intravenous (heparin) or intragastric (warfarin)As given in this study (rat).

    Source sentences

    Summary
    All animals receiving BPC 157 in addition (BPC 157 μg+L-NAME; BPC 157 μg+L-arginine, BPC 157 μg+L-NAME+L-arginine), exhibited decreased haemorrhage and markedly counteracted thrombocytopenia.
    2 context sentences
    Summary · context
    Tail amputation, and/or i.v.-heparin (10 mg/kg), i.g.-warfarin (1.5 mg/kg/day for 3 days) were used in rats.
    Summary · context
    Treatment includes BPC 157, L-NAME, L-arginine, per se and their combination.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.